DOI: 10.1055/s-00043364

Pharmaceutical Fronts

References

Kelly MP, Hickey C, Makonnen S. et al.
Preclinical activity of the novel anti-prolactin receptor (PRLR) antibody-drug conjugate REGN2878-DM1 in PRLR-positive breast cancers.

Mol Cancer Ther 2017;
16 (07) 1299-1311

Download Bibliographical Data

Access:
Access: